BillionToOne, Inc. Class A Common Stock
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fet… Read more
BillionToOne, Inc. Class A Common Stock (BLLN) - Net Assets
Latest net assets as of December 2025: $480.11 Million USD
Based on the latest financial reports, BillionToOne, Inc. Class A Common Stock (BLLN) has net assets worth $480.11 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($632.65 Million) and total liabilities ($152.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $480.11 Million |
| % of Total Assets | 75.89% |
| Annual Growth Rate | 296.55% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 132.14 |
BillionToOne, Inc. Class A Common Stock - Net Assets Trend (2023–2025)
This chart illustrates how BillionToOne, Inc. Class A Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BillionToOne, Inc. Class A Common Stock (2023–2025)
The table below shows the annual net assets of BillionToOne, Inc. Class A Common Stock from 2023 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $480.11 Million | +186.20% |
| 2024-12-31 | $167.75 Million | +450.48% |
| 2023-12-31 | $30.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BillionToOne, Inc. Class A Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3411700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $754.85 Million | 157.23% |
| Total Equity | $480.11 Million | 100.00% |
BillionToOne, Inc. Class A Common Stock Competitors by Market Cap
The table below lists competitors of BillionToOne, Inc. Class A Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Organon & Co
NYSE:OGN
|
$1.64 Billion |
|
HEXPOL AB ser. B
LSE:0R7O
|
$1.64 Billion |
|
Inner Mongolia ERDOS Resources Co Ltd
SHG:600295
|
$1.64 Billion |
|
Primary Health Properties PLC
PINK:PHPRF
|
$1.64 Billion |
|
Forvia SE
PA:FRVIA
|
$1.64 Billion |
|
Red Cat Holdings Inc
NASDAQ:RCAT
|
$1.64 Billion |
|
Songcheng Performance Develop
SHE:300144
|
$1.64 Billion |
|
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
|
$1.64 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BillionToOne, Inc. Class A Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 167,753,000 to 480,105,000, a change of 312,352,000 (186.2%).
- Net income of 7,454,000 contributed positively to equity growth.
- Other factors increased equity by 304,898,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $7.45 Million | +1.55% |
| Other Changes | $304.90 Million | +63.51% |
| Total Change | $- | 186.20% |
Book Value vs Market Value Analysis
This analysis compares BillionToOne, Inc. Class A Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.81x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 104.69x to 6.81x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $0.68 | $71.34 | x |
| 2024-12-31 | $3.75 | $71.34 | x |
| 2025-12-31 | $10.48 | $71.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BillionToOne, Inc. Class A Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.44%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.32x
- Recent ROE (1.55%) is above the historical average (-98.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | -271.32% | -115.27% | 0.37x | 6.29x | $-85.73 Million |
| 2024 | -24.78% | -27.24% | 0.51x | 1.80x | $-58.35 Million |
| 2025 | 1.55% | 2.44% | 0.48x | 1.32x | $-40.56 Million |
Industry Comparison
This section compares BillionToOne, Inc. Class A Common Stock's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $482,684,274
- Average return on equity (ROE) among peers: -68.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BillionToOne, Inc. Class A Common Stock (BLLN) | $480.11 Million | -271.32% | 0.32x | $1.64 Billion |
| Agilent Technologies Inc (A) | $4.16 Billion | 9.64% | 0.80x | $31.54 Billion |
| Amer Bio Medica (ABMC) | $2.66 Million | -28.23% | 1.26x | $3.55K |
| ADCNF (ADCNF) | $852.85 Million | 37.00% | 2.65x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $2.00 Million |
| ANGLE plc (ANPCF) | $3.82 Million | -94.09% | 0.43x | $34.42 Million |
| SeqLL Inc. (ATLN) | $4.37 Million | -93.77% | 0.93x | $36.29K |
| Avricore Health Inc (AVCRF) | $-37.20K | 0.00% | 0.00x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $3.76 Million | -397.87% | 1.13x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $52.50 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-4.04 Million | 0.00% | 0.00x | $5.08 Million |